title: [Therapeutic options and controversies in the management of prostate cancer].
abstract: Many improvements have been made regarding the management of prostate cancer. The standard therapeutic options for localised prostate cancer remain radical prostatectomy, external beam radiation therapy, and brachytherapy. However, some minimally invasive treatments are being investigated, including high intensity focused ultrasound and cryotherapy. In the future these therapies may replace standard treatments in selected patients. On the other hand, only few advances have been made in the treatment of non-localised prostate cancer. Locally advanced cancer is treated with combination of radiotherapy and hormonotherapy, and metastatic cancer is treated with hormone therapy. Docetaxel may improve patient survival in hormone-refractory disease.
authors.affiliation: Service d'urologie, hôpital Cochin, 75679 Paris 14. michael.peyromaure@cch.ap-hop-paris.fr
authors.forename: Michaël
authors.initials: M
authors.lastname: Peyromaure
authors.forename: Nicolas
authors.initials: N
authors.lastname: Thiounn
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic; D001918:Brachytherapy; D003131:Combined Modality Therapy; D017679:Cryotherapy; D000077143:Docetaxel; D005544:Forecasting; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010166:Palliative Care; D018579:Patient Selection; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use; D014464:Ultrasonic Therapy
chemical_list: D000726:Androgen Antagonists; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel